Eli Lilly (LLY) stock news

Eli Lilly (LLY) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-11-10 20:18:14 UTC#611285duplicateconfirmednews

FDA mandates NAION blindness risk warning labels for all GLP-1 weight-loss medications

guardianimportance 0.40trust 0.80Food and Drug Administration 0Novo Nordisk A/S -0.40Eli Lilly and Company -0.40+2 entities

2026-11-10 13:00:53 UTC#608246newreportednews

Access to Medicine Foundation warns GLP-1 weight-loss drug focus may threaten global insulin supply

guardianimportance 0.40trust 0.70Novo Nordisk A/S -0.20Eli Lilly and Company -0.20Access to Medicine Foundation 0+2 entities

2026-11-10 13:00:00 UTC#608152newconfirmedpress release

Eli Lilly launches Life Doesn't Slow Down marketing campaign for Foundayo weight-loss pill

yahooimportance 0.30trust 0.90Eli Lilly and Company +0.30Foundayo +0.30Leanne Morgan +0.20

2026-11-10 07:52:40 UTC#606123duplicateconfirmednews

FDA warns of potential vision loss risk associated with GLP-1 weight-loss drugs

cnbcimportance 0.30trust 0.80Food and Drug Administration 0Novo Nordisk A/S -0.40Eli Lilly and Company -0.40

2026-11-10 00:07:14 UTC#604295updateconfirmednews

Hims & Hers CFO cites Eli Lilly partnership for retention, explains Q3 weight-loss marketing pacing

first_squawkimportance 0.40trust 0.70Hims & Hers Health, Inc. +0.20Eli Lilly and Company +0.30

2026-11-09 20:28:04 UTC#602892duplicateconfirmednews

FDA mandates eye risk warning labels for Eli Lilly and Novo Nordisk weight-loss drugs

seeking alphaimportance 0.40trust 0.70Eli Lilly and Company -0.40Novo Nordisk A/S -0.40

2026-11-09 19:27:00 UTC#602648duplicateconfirmednews

Eli Lilly to seek FDA approval for Foundayo to treat sleep apnea, competing with Novo Nordisk's oral Wegovy

yahooimportance 0.30trust 0.70Eli Lilly and Company +0.50Foundayo +0.50Novo Nordisk A/S -0.20+2 entities

2026-11-09 17:55:24 UTC#602430duplicateconfirmednews

FDA mandates NAION eye risk warning labels for Novo Nordisk and Eli Lilly GLP-1 drugs

zerodha pulseimportance 0.40trust 0.70U.S. Food and Drug Administration 0Novo Nordisk A/S -0.40Eli Lilly and Company -0.40+2 entities

2026-11-09 17:10:55 UTC#601957newconfirmednews

Hims & Hers shares decline ahead of earnings; company guides for $893M revenue and $0.06 EPS

Open sourceimportance 0.40trust 0.50Hims & Hers Health, Inc. -0.30Eli Lilly and Company +0.20Zepbound +0.20+1 entities

2026-11-09 16:56:00 UTC#601849duplicateconfirmednews

FDA mandates NAION eye risk warning labels for Novo Nordisk and Eli Lilly GLP-1 drugs, WSJ reports

dow_jonesimportance 0.40trust 0.90Novo Nordisk A/S -0.40Eli Lilly and Company -0.40U.S. Food and Drug Administration -0.20+2 entities

2026-11-09 16:30:15 UTC#601681duplicateconfirmednews

Eli Lilly's Foundayo weight loss pill shows efficacy in sleep apnea clinical trials

bloombergimportance 0.30trust 0.90Eli Lilly and Company +0.50Foundayo +0.50

2026-11-09 15:38:00 UTC#601364duplicateconfirmednews

Eli Lilly reports positive late-stage clinical trial results for Foundayo in treating obstructive sleep apnea

dow_jonesimportance 0.30trust 0.80Eli Lilly and Company +0.60Foundayo +0.60Food and Drug Administration +0.40+1 entities

2026-11-09 14:54:39 UTC#601030duplicateconfirmednews

US FDA mandates new eye risk warning labels for Novo Nordisk's Ozempic and Eli Lilly's Zepbound

reutersimportance 0.60trust 0.90U.S. Food and Drug Administration -0.30Novo Nordisk A/S -0.40Eli Lilly and Company -0.40

2026-11-09 14:53:01 UTC#600992newconfirmednews

FDA mandates NAION eye risk warnings for Eli Lilly and Novo Nordisk GLP-1 weight-loss and diabetes drugs

reutersimportance 0.70trust 0.90Eli Lilly and Company -0.40Novo Nordisk A/S -0.40U.S. Food and Drug Administration -0.20+2 entities

2026-11-09 14:50:04 UTC#601027duplicateconfirmednews

Eli Lilly's Foundayo oral weight-loss drug meets primary goal in late-stage sleep apnea study

reutersimportance 0.30trust 0.90Eli Lilly and Company +0.50Foundayo +0.50

2026-11-09 14:41:20 UTC#600968duplicateconfirmednews

Eli Lilly weight-loss pill meets primary goal in late-stage sleep apnea study

reutersimportance 0.30trust 0.90Eli Lilly and Company +0.60

2026-11-09 14:38:50 UTC#600877duplicateconfirmednews

Eli Lilly's Foundayo shows 52-week efficacy in sleep apnea, weight, and cardiovascular risk reduction

first_squawkimportance 0.30trust 0.70Eli Lilly and Company +0.60Foundayo +0.60

2026-11-09 14:30:01 UTC#600819newconfirmednews

Eli Lilly's Foundayo obesity pill meets primary endpoints in sleep apnea trial; FDA filing planned for year-end

cnbcimportance 0.70trust 0.80Eli Lilly and Company +0.80Foundayo +0.80

2026-11-09 14:30:00 UTC#600828updateconfirmedpress release

Eli Lilly's Foundayo (orforglipron) shows 44% reduction in sleep apnea breathing interruptions in clinical trial

pr newswireimportance 0.50trust 0.90Eli Lilly and Company +0.60orforglipron +0.60

2026-11-06 19:25:31 UTC#592218duplicateconfirmednews

Eli Lilly and Hims & Hers partnership to distribute Zepbound and Foundayo confirmed

yahooimportance 0.30trust 0.60Eli Lilly and Company +0.60Hims & Hers Health, Inc. +0.60Zepbound +0.50+1 entities